IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1

Blood

Volumn 123, Issue 15, 2014, Pages 2401-2411

  Hsieh, Mo Ying ^a,b   Van Etten, Richard A ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN BCL X; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; IKBKB PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B LYMPHOBLAST; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PHYSIOLOGY; SOUTHERN BLOTTING; WESTERN BLOTTING;

ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; I-KAPPA B KINASE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICROSCOPY, CONFOCAL; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSDUCTION, GENETIC;

EID: 84901723292     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-547943     Document Type: Article

References (50)

1. Mahon FX, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
2. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-1042. (Pubitemid 32267973)
3. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
4. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
5. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013;2013:189-200.
6. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-1630.
7. Van Etten RA. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene. 2002;21(56):8643-8651. (Pubitemid 36084196)
8. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006;103(45):16870-16875. (Pubitemid 44737345)
9. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001;97(1):4-13. (Pubitemid 32061237)
10. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431-436. (Pubitemid 44050137)
11. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280-288. (Pubitemid 38610351)
12. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene. 1997;15(19):2267-2275. (Pubitemid 27496978)
13. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin ASJ Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12(7):968-981. (Pubitemid 28204604)
14. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol. 2003;31(6):504-511.
15. Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM. Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2004;45(6):1181-1184. (Pubitemid 38584900)
16. Mihailovic T, Marx M, Auer A, et al. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res. 2004;64(24):8939-8944. (Pubitemid 39665501)
17. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005;106(4):1392-1399. (Pubitemid 41129606)
18. Nakano H, Shindo M, Sakon S, et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A. 1998;95(7):3537-3542.
19. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92(10):3780-3792. (Pubitemid 28525205)
20. Gavrilescu LC, Van Etten RA. Applications of murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Moser P, Ruggeri B, eds. Current Protocols in Pharmacology. Ch 14. Pagosa Springs, CO: John Wiley & Sons, Inc.; 2008.
21. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189(9):1399-1412. (Pubitemid 29227526)
22. Warren D, Griffin DS, Mainville C, Rosenberg N. The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J Virol. 2003;77(8):4617-4625. (Pubitemid 36402811)
23. Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12(1):27-37. (Pubitemid 36945035)
24. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.
25. Chen F, Demers LM, Vallyathan V, Lu Y, Castranova V, Shi X. Involvement of 59-flanking kappaB-like sites within bcl-x gene in silica-induced Bcl-x expression. J Biol Chem. 1999;274(50):35591-35595. (Pubitemid 129512856)
26. Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci U S A. 1990;87(12):4727-4731.
27. Gishizky ML, Witte ON. BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. Curr Top Microbiol Immunol. 1992;182:65-72. (Pubitemid 23018866)
28. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70(6):901-910.
29. Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011;18(2):89-97.
30. Ohno R. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2010;5(4):213-221.
31. Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999;94(8):2844-2853. (Pubitemid 29477313)
32. Baumgartner B, Weber M, Quirling M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16(10):2062-2071. (Pubitemid 35203449)
33. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301-2307.
34. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169. (Pubitemid 40720758)
35. Jenkins C, Hewamana S, Gilkes A, et al. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol. 2008;143(5):661-671.
36. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99(25):16220-16225. (Pubitemid 35462776)
37. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105(2):804-811. (Pubitemid 40070768)
38. Jagani Z, Song K, Kutok JL, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors [published correction appears in Cancer Res. 2009;69(17):7130]. Cancer Res. 2009;69(16):6546-6555.
39. Albero MP, Vaquer JM, Andreu EJ, et al. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. Oncogene. 2010;29(22):3276-3286.
40. Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood. 2010;115(11):2241-2250.
41. Cilloni D, Messa F, Arruga F, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia. 2006;20(1):61-67.
42. Duncan EA, Goetz CA, Stein SJ, et al. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther. 2008;7(2):391-397. (Pubitemid 351302532)
43. Lounnas N, Frelin C, Gonthier N, et al. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int J Cancer. 2009;125(2):308-317.
44. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 1999;189(11):1839-1845. (Pubitemid 29272700)
45. Adli M, Merkhofer E, Cogswell P, Baldwin AS. IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. PLoS ONE. 2010;5(2):e9428.
46. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49-62. (Pubitemid 46012014)
47. Kaisho T, Takeda K, Tsujimura T, et al. IkappaB kinase alpha is essential for mature B cell development and function. J Exp Med. 2001;193(4):417-426. (Pubitemid 32524473)
48. Morotti A, Cilloni D, Pautasso M, et al. NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am J Hematol. 2006;81(12):938-945. (Pubitemid 44864452)
49. Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013;19(11):1513-1517.
50. Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550-3560.